Waters raises 2025 profit guidance as Q2 sales rise 9% to $771 million
Waters reported second-quarter 2025 sales of $771 million, up 9% as reported and 8% in constant currency, and non-GAAP EPS of $2.95, up 12% from $2.63 a year earlier. The company raised its full-year 2025 non-GAAP EPS guidance to $12.95 to $13.05 and its constant currency sales growth guidance to +5.5% to +7.5%, which points to stronger expected results for shareholders. The release also says the company is integrating a proposed combination with BD Biosciences & Diagnostic Solutions.
Key points
- Q2 2025 sales were $771 million, up 9% as reported and 8% in constant currency, versus $709 million in Q2 2024.
- GAAP diluted EPS was $2.47, compared with $2.40 a year earlier; non-GAAP EPS was $2.95, compared with $2.63.
- Full-year 2025 non-GAAP EPS guidance was raised to $12.95 to $13.05, and constant currency sales growth guidance to +5.5% to +7.5%.
- Third-quarter 2025 non-GAAP EPS is expected to be $3.15 to $3.25.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.